肾癌的代谢途径：当前疗法与未来方向
Metabolic Pathways in Kidney Cancer: Current Therapies and Future Directions.
作者信息
Rathmell W Kimryn, Rathmell Jeffrey C, Linehan W Marston
机构信息
W. Kimryn Rathmell and Jeffrey C. Rathmell, Vanderbilt-Ingram Cancer Center and Vanderbilt University Medical Center, Nashville, TN; W. Marston Linehan, National Institutes of Health, Bethesda, MD.
出版信息
J Clin Oncol. 2018 Oct 29:JCO2018792309. doi: 10.1200/JCO.2018.79.2309.
BACKGROUND
Renal cell carcinoma (RCC) has become known as a metabolic disease, owing to the diverse array of metabolic defects and perturbations that occur as a result of the unique genetics that can drive these tumors. Recent attention to this feature of RCCs has fueled interest in targeting metabolism as a therapeutic strategy.
METHODS
We conducted a literature search to develop themes around discrete pathways or processes of cellular metabolism, provide a framework for understanding emerging therapeutic strategies, and consider future interventions.
RESULTS
Defects occur in metabolic pathways ranging from glycolysis to mitochondrial function and affect not only the tumor cell functionality, but also the local environment. We identified opportunities for therapeutic intervention associated with each pathway.
CONCLUSION
The metabolism of RCC cells presents a special environment of tumor susceptibilities, with opportunities for novel imaging applications and treatment paradigms that are being tested in monotherapy or as adjuncts to targeted or immune-based strategies.
背景
由于肾细胞癌（RCC）独特的遗传学特征可驱动肿瘤发生，进而引发多种代谢缺陷和紊乱，因此它已被视为一种代谢性疾病。近期对RCC这一特征的关注激发了人们将代谢作为治疗策略靶点的兴趣。
方法
我们进行了文献检索，以围绕细胞代谢的离散途径或过程展开主题探讨，为理解新兴治疗策略提供框架，并考虑未来的干预措施。
结果
从糖酵解到线粒体功能，代谢途径均存在缺陷，这不仅影响肿瘤细胞功能，还影响局部环境。我们确定了与每条途径相关的治疗干预机会。
结论
RCC细胞的代谢呈现出肿瘤易感性的特殊环境，为新型成像应用和治疗模式提供了机会，这些正在单药治疗中或作为靶向治疗或免疫治疗策略的辅助手段进行测试。
Zotero 插件